drugset / Trial / NCT01036594

Ketoconazole and Dexamethasone in Prostate Cancer

NCT01036594

Phase 2 Completed 32 enrolled University of California, San Francisco
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open label, phase II, single center trial of ketoconazole/dexamethasone to determine if the administration of ketoconazole/dexamethasone, after disease progression with ketoconazole/hydrocortisone slows or reverses disease progression in men with progressive prostate cancer.

Timeline

Start
2009-12-11
Primary completion
2012-12-11
Completion
2014-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.5 mg Oral
Subject Hydrocortisone Other / unclassified 10 mg Oral
Subject Hydrocortisone Other / unclassified 20 mg Oral
Subject Ketoconazole Small molecule 400 mg Oral

Indications